Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
CYTR's Cash to Debt is ranked higher than
95% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. CYTR: No Debt )
CYTR' s 10-Year Cash to Debt Range
Min: 2.95   Max: No Debt
Current: No Debt

Interest Coverage No Debt
CYTR's Interest Coverage is ranked higher than
87% of the 582 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYTR: No Debt )
CYTR' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: -0.20
M-Score: 118.24
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -46697.00
CYTR's Operating margin (%) is ranked lower than
52% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. CYTR: -46697.00 )
CYTR' s 10-Year Operating margin (%) Range
Min: -21052   Max: -21.16
Current: -46697

-21052
-21.16
Net-margin (%) -43897.00
CYTR's Net-margin (%) is ranked lower than
52% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. CYTR: -43897.00 )
CYTR' s 10-Year Net-margin (%) Range
Min: -18984.04   Max: 408
Current: -43897

-18984.04
408
ROE (%) -78.08
CYTR's ROE (%) is ranked higher than
62% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. CYTR: -78.08 )
CYTR' s 10-Year ROE (%) Range
Min: -342.91   Max: 1.39
Current: -78.08

-342.91
1.39
ROA (%) -57.28
CYTR's ROA (%) is ranked higher than
61% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. CYTR: -57.28 )
CYTR' s 10-Year ROA (%) Range
Min: -201.4   Max: 1.13
Current: -57.28

-201.4
1.13
ROC (Joel Greenblatt) (%) -14749.53
CYTR's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. CYTR: -14749.53 )
CYTR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -12894.39   Max: -25.55
Current: -14749.53

-12894.39
-25.55
EBITDA Growth (3Y)(%) -7.20
CYTR's EBITDA Growth (3Y)(%) is ranked higher than
75% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. CYTR: -7.20 )
CYTR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -67.3   Max: 144.7
Current: -7.2

-67.3
144.7
» CYTR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2012

CYTR Guru Trades in Q2 2012

Jim Simons Sold Out
» More
Q4 2013

CYTR Guru Trades in Q4 2013

Steven Cohen 205,100 sh (New)
» More
Q1 2014

CYTR Guru Trades in Q1 2014

George Soros 81,800 sh (New)
Paul Tudor Jones 51,898 sh (New)
Steven Cohen Sold Out
» More
Q2 2014

CYTR Guru Trades in Q2 2014

Paul Tudor Jones Sold Out
George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CYTR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Sold Out $2.92 - $5.31 $ 2.55-33%0
George Soros 2014-03-31 New Buy$3.18 - $8.08 $ 2.55-57%81800
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.82
CYTR's P/B is ranked higher than
91% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. CYTR: 1.82 )
CYTR' s 10-Year P/B Range
Min: 1.3   Max: 64.65
Current: 1.82

1.3
64.65
EV-to-EBIT -1.12
CYTR's EV-to-EBIT is ranked higher than
84% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CYTR: -1.12 )
CYTR' s 10-Year EV-to-EBIT Range
Min: -17.5   Max: 0.1
Current: -1.12

-17.5
0.1
Current Ratio 5.14
CYTR's Current Ratio is ranked higher than
75% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. CYTR: 5.14 )
CYTR' s 10-Year Current Ratio Range
Min: 1.04   Max: 75.75
Current: 5.14

1.04
75.75
Quick Ratio 5.14
CYTR's Quick Ratio is ranked higher than
76% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. CYTR: 5.14 )
CYTR' s 10-Year Quick Ratio Range
Min: 1.04   Max: 75.75
Current: 5.14

1.04
75.75

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.99
CYTR's Price/Net Cash is ranked higher than
97% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 53.79 vs. CYTR: 1.99 )
CYTR' s 10-Year Price/Net Cash Range
Min: 0.57   Max: 458
Current: 1.99

0.57
458
Price/Net Current Asset Value 1.91
CYTR's Price/Net Current Asset Value is ranked higher than
97% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 31.40 vs. CYTR: 1.91 )
CYTR' s 10-Year Price/Net Current Asset Value Range
Min: 0.44   Max: 601.65
Current: 1.91

0.44
601.65
Price/Tangible Book 1.82
CYTR's Price/Tangible Book is ranked higher than
94% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9.45 vs. CYTR: 1.82 )
CYTR' s 10-Year Price/Tangible Book Range
Min: 0.32   Max: 65.43
Current: 1.82

0.32
65.43
Earnings Yield (Greenblatt) -89.30
CYTR's Earnings Yield (Greenblatt) is ranked lower than
52% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. CYTR: -89.30 )
CYTR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 908.1   Max: 3114.3
Current: -89.3

908.1
3114.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CX5N.Germany,
CytRx Corp is a Delaware corporation, incorporated in 1985. The Company is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes three clinical-stage drug candidates in various stages of development: Aldoxorubicin, Tamibarotene, and Bafetinib. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors. Tamibarotene is an orally available, synthetic retinoid, rationally designed to overcome resistance and reduce the toxic side effects of differentiation therapy with all-trans retinoic acid, a component of the current first-line treatment for acute promyelocytic leukemia, or APL. Bafetinib (formerly INNO-406) is an orally bioavailable, rationally-designed inhibitor of several Src kinases developed by the Japanese pharmaceutical company, Nippon Shinyaku, to overcome some of the limitations of Gleevec and other tyrosine kinase inhibitors in resistant chronic myelogenous leukemia. The Company do not have manufacture supplies of aldoxorubicin or any of our other product candidates accordingly it is dependent upon third-party manufactures, or potential future strategic alliance partners, to manufacture these supplies. The Company has manufacturing supply arrangements in place with respect to a portion of the clinical supplies needed for the clinical development programs for aldoxorubicin. The Company's plan is to establish its own sales force and marketing capability in order to commercialize aldoxorubicin in the U.S. and to seek a marketing partner for commercialization in other territories. It is subjected to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials.
» More Articles for CYTR

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: CYTR, API, CLGX, PLBC, ARTC Mar 05 2012 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CFO Buys Highlight: CYTR, PZZI, AGYS, PLBC Feb 27 2012 
CytRx Corp. Reports Operating Results (10-K) Mar 11 2011 
CytRx Corp. Reports Operating Results (10-Q) Nov 08 2010 
CytRx Corp. Reports Operating Results (10-Q) Aug 09 2010 
CytRx Corp. Reports Operating Results (10-Q) May 06 2010 
CytRx Corp. Reports Operating Results (10-Q) Nov 09 2009 
CytRx Reports 2009 Second Quarter Financial Results Aug 10 2009 
CytRx Corp. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ... Dec 15 2014
CytRx Falls on Written FDA Notice for Aldoxorubicin Study Dec 04 2014
CytRx Receives Written FDA Communication Regarding Partial Clinical Hold for Aldoxorubicin Clinical... Dec 03 2014
CytRx Receives Written FDA Communication Regarding Partial Clinical Hold for Aldoxorubicin Clinical... Dec 03 2014
CytRx to Present at the Oppenheimer 25th Annual Healthcare Conference Dec 02 2014
CytRx to Present at the Oppenheimer 25th Annual Healthcare Conference Dec 02 2014
CytRx Falls on Partial Study Hold on Oncology Candidate Nov 19 2014
FDA puts partial hold on CytRx cancer drug trials Nov 18 2014
CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials Nov 18 2014
CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials Nov 18 2014
Amarantus passe un accord d’option exclusive pour l’acquisition auprès de Lonza d’un... Nov 17 2014
CYTRX CORP Financials Nov 14 2014
10-Q for CytRx Corp. Nov 06 2014
CytRx Reports 2014 Third Quarter Financial Results Nov 04 2014
CYTRX CORP Files SEC form 10-Q, Quarterly Report Nov 04 2014
CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition Nov 04 2014
CytRx Reports 2014 Third Quarter Financial Results Nov 04 2014
CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium Oct 30 2014
CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium Oct 30 2014
CytRx Announces Publication of Preclinical Glioblastoma Data in Neoplasia Oct 29 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK